|
Last Updated: Nov 17th, 2006 - 22:35:04 |
Latest Research
:
Pharmacology
:
Hypnotics
:
Ramelteon
Ramelteon shows less potential to foster abuse and dependence
As part of the effort to develop effective behavioral and medical sleep therapies, scientists consider the potential for dependence and abuse associated with prescription sleep drugs. This line of research has produced findings showing that a recently approved prescription sleep drug may spare users the potential for dependence and abuse found with other sleep aids. Laboratory studies of the effects of ramelteon suggest that the drug's targeting of the brain's melatonin receptors rather than its benzodiazepine receptors make its subjective side effects different from those of old and new sedative hypnotics.
Jun 5, 2006, 16:19
Latest Research
:
Pharmacology
:
Hypnotics
:
Ramelteon
Ramelteon showed significant reduction in time to fall asleep
Results of a sub-analysis from a Phase III clinical study showed that ROZEREMTM (ramelteon) significantly reduced time to fall asleep in adults with chronic insomnia and showed no evidence of rebound insomnia or withdrawal effects. The results were presented today at the 2006 Annual Meeting of the American Academy of Neurology.
Apr 3, 2006, 23:35
Latest Research
:
Pharmacology
:
Hypnotics
:
Ramelteon
FDA Approves Ramelteon, the First 'No Abuse' Drug for Insomnia
Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREM(TM) (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ROZEREM for long-term use in adults.
Jul 23, 2005, 23:56
Latest Research
:
Pharmacology
:
Hypnotics
:
Ramelteon
FDA approved Ramelteon
Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREMTM (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ROZEREM for long-term use in adults.
Jul 23, 2005, 18:12
|
